1. Search Result
Search Result
Results for "

Leishmania promastigotes

" in MedChemExpress (MCE) Product Catalog:

29

Inhibitors & Agonists

1

Peptides

10

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-76228

    Pyrazole

    Parasite iGluR Infection
    1H-pyrazole (Pyrazole) is a five-membered heterocyclic compound, and its derivatives are orally effective antimalarial and antileishmanial agents with the potential to modulate targets such as alcohol dehydrogenase and NMDA receptors. 1H-pyrazole derivatives exhibit inhibitory effects on Plasmodium berghei in infected mice and on promastigotes of Leishmania aethiopica, respectively. 1H-pyrazole can be used in research related to malaria and leishmaniasis .
    1H-pyrazole
  • HY-124481

    COX Reactive Oxygen Species (ROS) NO Synthase Keap1-Nrf2 Heme Oxygenase (HO) Amyloid-β Parasite Infection Neurological Disease Inflammation/Immunology Cancer
    Oleocanthal is an orally active phenolic seciridoid compound. Oleocanthal can be extracted from olive oil. Oleocanthal inhibits COX-1 and COX-2, reduces ROS and NO, and upregulates Nrf-2 and HO-1. Oleocanthal reduces deposition. Oleocanthal exhibits anti-Leishmania activity against promastigotes and amastigotes of L. major, with IC50 values of 18.7 and 87 μg/mL, respectively. Oleocanthal exhibits anticancer activity against colon, breast, liver, and melanoma cancers. Oleocanthal also exhibits anti-inflammatory and neuroprotective properties. Oleocanthal can be used in Alzheimer's disease research .
    Oleocanthal
  • HY-W016813

    Parasite Infection
    trans-Aconitic acid is an orally active aconitase inhibitor that non-competitively inhibits the conversion of citric acid to cis-aconitic acid and competitively inhibits the conversion of cis-aconitic acid to isocitric acid. trans-Aconitic acid inhibits the growth of Leishmania donovani promastigotes, the transformation of Leishmania donovani amastigotes to promastigotes, and the in vitro proliferation of Leishmania donovani amastigotes within macrophages in vitro. trans-Aconitic acid can be used in research related to visceral leishmaniasis (kala-azar) .
    trans-Aconitic acid
  • HY-N7926

    Environmental Pollutants Apoptosis Parasite TNF Receptor Interleukin Related Infection Inflammation/Immunology
    Pentadecane is an orally active natural plant volatile alkane with anti-inflammatory, analgesic, antipyretic and anti-leishmanial activities. Pentadecane presents IC50 values of 65.3 μM, 60.5 μM and 194.8 μM against Leishmania infantum promastigotes, amastigotes and intracellular amastigotes, respectively. Pentadecane downregulates the mRNA expression of TNF-α and IL-12 and inhibits the release of inflammatory mediators. Pentadecane arrests the cell cycle of Leishmania infantum and induces apoptosis. Pentadecane can be applied to the research of inflammation and leishmaniasis .
    Pentadecane
  • HY-155520

    Parasite Infection
    Antileishmanial agent-19 (Compound F27) is an antileishmanial agent, with a IC50 of 3.39 μM for L. donovani promastigotes. Antileishmanial agent-19 inhibits Leishmania prolyl-tRNA synthetase. Antileishmanial agent-19 inhibits host PI3K/Akt/CREB axis-mediated IL-10 secretion. Antileishmanial agent-19 induces autophagy-mediated apoptosis in L. donovani promastigotes. Antileishmanial agent-19 reduces parasite burden in L.d-infected animals .
    Antileishmanial agent-19
  • HY-162066

    Parasite Infection
    DNDI-6174 is an orally active Leishmania cytochrome b (Qi site of cytochrome bc1 complex/complex III) inhibitor. DNDI-6174 binds to the Qi site of Leishmania cytochrome b, inhibits cytochrome bc1 complex activity in the parasite's electron transport chain across promastigote and axenic amastigote stages. DNDI-6174 reduces parasite burden in rodent models, inhibits growth of various Leishmania species, drug-resistant clinical isolates, and Trypanosoma cruzi, with marginal activity against Trypanosoma brucei. DNDI-6174 can be used for the research of visceral leishmaniasis, cutaneous leishmaniasis .
    DNDI-6174
  • HY-134467

    Parasite NO Synthase Infection
    Phylloflavan is an antileishmanial (Antileishmanial) agent with an EC50 of 3.2 nM against intracellular amastigotes of Leishmania donovani. Phylloflavan is isolated from Phyllocldus plants. Phylloflavan induces moderate levels of NO release. Phylloflavan also inhibits the cytopathic effect of encephalomyocarditis virus on L929 fibroblasts (38 U/mL) .
    Phylloflavan
  • HY-169728

    Hexokinase Parasite Infection
    SID 24785302 is a hexokinase inhibitor with antiparasitic activity. SID 24785302 exhibits activity against T. brucei and Leishmania. SID 24785302 can be used for the research of mitochondrial DNA disorders and parasitic infection .
    SID 24785302
  • HY-151935

    Parasite Infection
    Antileishmanial agent-13 is a quinoline-isatin hybrid, acts as an antileishmanial agent against L. Major Leishmania strain. Antileishmanial agent-13 acquires the antileishmanial activity via the anti-folate mechanism. Antileishmanial agent-13 has potent inhibition against both promastigote and amastigote forms with IC50s of 0.604 μM and 0.508 μM, respectively .
    Antileishmanial agent-13
  • HY-N3702

    Syk Infection Inflammation/Immunology
    Dehydroabietinol is a SYK inhibitor with an IC50 of 46.4 μM. Dehydroabietinol inhibits the growth of Trypanosoma cruzi epimastigotes, Leishmania braziliensis promastigotes and Leishmania infantum promastigotes. Dehydroabietinol indirectly inhibits the growth of Plasmodium falciparum, alters the erythrocyte membrane, and induces spherostomatocyte transformation and endovesicle formation. Dehydroabietinol can be used in studies related to immune-mediated diseases, Chagas disease, leishmaniasis and malaria .
    Dehydroabietinol
  • HY-149093

    Parasite Infection
    Antileishmanial agent-14 is a sulfuretin analog with potential activity against the parasite Leishmania donovani promastigotes (IC50=4.1 μM). Antileishmanial agent-14 also inhibits infection by L. donovani amastigotes (IC50=11.1 μM) .
    Antileishmanial agent-14
  • HY-159097

    Parasite Infection
    T.cruzi-IN-4 (Compound 21) is an anti-parasitic agent. T.cruzi-IN-4 inhibits the trypomastigote and amastigote form of Trypanosoma cruzi with IC50 of 0.033 μM (120 h), T.cruzi-IN-4 inhibits the promastigote and amastigote form of Leishmania infantum with IC50 of 28.74 and 61.82 μM. T.cruzi-IN-4 inhibits Leishmania amazonensis promastigote form with IC50 of 18.38 μM .
    T.cruzi-IN-4
  • HY-149957

    Parasite Infection
    Antileishmanial agent-16 (compound 14c) is an anti-Leishmania agent. Antileishmanial agent-16 has superior anti-Leishmania major promastigotes activity (IC50 = 0.59 µM) and anti-Leishmania major amastigotes activity (IC50 = 0.81 µM). Antileishmanial agent-16 has good safety to mammalian cells (VERO cells) .
    Antileishmanial agent-16
  • HY-P11155

    Parasite Infection
    Halictine 2 is an antimicrobial peptide. Halictine 2 exhibits promising anti-parasitic activity against Leishmania spp., targeting both the extracellular infective metacyclic promastigotes and intracellular amastigotes. Halictine 2 can be used for the study of leishmaniases .
    Halictine 2
  • HY-168918

    Parasite Dihydrofolate reductase (DHFR) Infection
    Insecticidal agent 19 (Compound 7b) exhibits antimalarial activity by inhibiting dihydrofolate reductase-thymidylate synthase (DHFR-TS) and pteridine reductase 1 (PTR1) through the folic acid metabolic pathway. Insecticidal agent 19 inhibits Leishmania major promastigote and amastigote with IC50 of 1.43 μM and 3.78 μM .
    Insecticidal agent 19
  • HY-178033

    Parasite Mitochondrial Metabolism Reactive Oxygen Species (ROS) Infection
    Antileishmanial agent-35 (Compound 6) is an antileishmanial agent with an IC50 of 0.29μM for promastigotes of Leishmania amazonensis. Antileishmanial agent-35 significantly decreases the mitochondrial membrane potential and ATP levels, and further increases the production of ROS by a blockage in the electron transport chain, where ubiquinone intervenes. Antileishmanial agent-35 can be used for cutaneous leishmaniases research .
    Antileishmanial agent-35
  • HY-N7926S

    Isotope-Labeled Compounds Parasite TNF Receptor Interleukin Related Apoptosis Infection Inflammation/Immunology
    Pentadecane-d32 is the deuterium labeled Pentadecane (HY-N7926). Pentadecane is an orally active natural plant volatile alkane with anti-inflammatory, analgesic, antipyretic and anti-leishmanial activities. Pentadecane presents IC50 values of 65.3 μM, 60.5 μM and 194.8 μM against Leishmania infantum promastigotes, amastigotes and intracellular amastigotes, respectively. Pentadecane downregulates the mRNA expression of TNF-α and IL-12 and inhibits the release of inflammatory mediators. Pentadecane arrests the cell cycle of Leishmania infantum and induces apoptosis. Pentadecane can be applied to the research of inflammation and leishmaniasis .
    Pentadecane-d32
  • HY-N7926R

    Parasite Reference Standards TNF Receptor Interleukin Related Apoptosis Infection Inflammation/Immunology
    Pentadecane (Standard) is the analytical standard of Pentadecane (HY-N7926). This product is intended for research and analytical applications. Pentadecane is an orally active natural plant volatile alkane with anti-inflammatory, analgesic, antipyretic and anti-leishmanial activities. Pentadecane presents IC50 values of 65.3 μM, 60.5 μM and 194.8 μM against Leishmania infantum promastigotes, amastigotes and intracellular amastigotes, respectively. Pentadecane downregulates the mRNA expression of TNF-α and IL-12 and inhibits the release of inflammatory mediators. Pentadecane arrests the cell cycle of Leishmania infantum and induces apoptosis. Pentadecane can be applied to the research of inflammation and leishmaniasis .
    Pentadecane (Standard)
  • HY-185556

    Parasite Infection
    14-Hydroxydehydroabietane is a ribosomal enzyme inhibitor. 14-Hydroxydehydroabietane exhibits in vitro antileishmanial activity against promastigotes, amastigotes and intracellular amastigotes of Leishmania infantum and Leishmania braziliensis. 14-Hydroxydehydroabietane induces ultrastructural changes in Leishmania braziliensis promastigotes. 14-Hydroxydehydroabietane reduces the infection rate of macrophages by Leishmania infantum and Leishmania braziliensis. 14-Hydroxydehydroabietane can be used for the research of leishmaniasis .
    14-Hydroxydehydroabietane
  • HY-N7236

    Parasite Fungal Infection
    Pervicoside B is a glycoside C isolated from Neothyone gibbosa sea cucumber. In vitro studies have shown that Pervicoside B has a potent antiparasitic effect against Leishmania mexicana, inhibiting 100% of promastigotes at 5-10 μg/mL. Pervicoside B also exhibits strong antifungal activity against Aspergillus niger, with MIC values ranging from 4.65 to 16.7 μg/mL. Pervicoside B has potential applications in the inhibition of parasitic infections and fungal diseases .
    Pervicoside B
  • HY-76228R

    Pyrazole (Standard)

    Reference Standards Parasite iGluR Infection Inflammation/Immunology
    1H-pyrazole (Standard) is the analytical standard of 1H-pyrazole. This product is intended for research and analytical applications. 1H-pyrazole (Pyrazole) is a five-membered heterocyclic compound, and its derivatives are orally effective antimalarial and antileishmanial agents with the potential to modulate targets such as alcohol dehydrogenase and NMDA receptors. 1H-pyrazole derivatives exhibit inhibitory effects on Plasmodium berghei in infected mice and on promastigotes of Leishmania aethiopica, respectively. 1H-pyrazole can be used in research related to malaria and leishmaniasis .
    1H-pyrazole (Standard)
  • HY-N19720

    Drug Derivative Parasite Infection
    Bractein is a natural aurone flavonoid with potential antioxidant activity. Bractein shows in vitro antileishmanial activity and inhibits promastigotes and intracellular amastigotes of Leishmania donovani. Bractein exhibits no obvious cytotoxicity against mammalian macrophages with an EC50 value > 25.0 μg/mL. Bractein can be used for the research of Leishmania .
    Bractein
  • HY-184205

    Parasite Infection
    LASSBio-1736 is a Cysteine protease inhibitor and antimalarial agent. LASSBio-1736 targets the promastigote form of Leishmania major. LASSBio-1736 can be used in the research of leishmaniasis .
    LASSBio-1736
  • HY-179584

    Parasite Infection
    Antileishmanial agent-38 (compound 197) is a host-directed small molecule antileishmanial agent exhibiting potent broad-spectrum activity against Leishmania spp. Antileishmanial agent-38 inhibits intracellular parasites primarily by targeting the host protein lysozyme, while also displaying direct activity against extracellular L. donovani promastigotes. Antileishmanial agent-38 can be used for leishmaniasis research .
    Antileishmanial agent-38
  • HY-183262

    Parasite Reactive Oxygen Species (ROS) Infection
    Antileishmanial agent-40 is an orally active and selective antileishmanial agent. Antileishmanial agent-40 elevates intracellular reactive oxygen species (ROS) levels in Leishmania donovani promastigotes. Antileishmanial agent-40 induces cell cycle arrest at the sub-G0/G1 phase in Leishmania donovani promastigotes, indicative of programmed-like parasite death. Antileishmanial agent-40 can be used for the research of leishmaniasis .
    Antileishmanial agent-40
  • HY-183621

    Parasite Reactive Oxygen Species (ROS) Autophagy Infection
    Antileishmanial agent-43 is a 3,4,5‑trisubstituted isoxazole with selective antileishmanial activity. Antileishmanial agent-43 shows IC50 values of 12.7 μM against Leishmania amazonensis promastigotes and 0.96 μM against intracellular amastigotes. Antileishmanial agent-43 induces ROS elevation, oxidative stress and mitochondrial dysfunction, resulting in lipid peroxidation, mitochondrial depolarization and ATP imbalance. Antileishmanial agent-43 causes cell shrinkage, phosphatidylserine externalization, plasma membrane permeabilization, and promotes autophagy. Antileishmanial agent-43 can be used for the research of leishmaniasis .
    Antileishmanial agent-43
  • HY-W676872

    COX Parasite Infection Inflammation/Immunology
    Dihydroflavokawin B is a selective COX-1 inhibitor with an IC50 of 1.22 μM. Dihydroflavokawin B weakly inhibits COX-2 and 5-LOX. Dihydroflavokawin B inhibits promastigote forms of Leishmania panamensis and Leishmania braziliensis. Dihydroflavokawin B inhibits rabbit platelet aggregation induced by Arachidonic acid, platelet activating factor, and adenosine diphosphate. Dihydroflavokawin B exhibits in vitro anti-inflammatory activity. Dihydroflavokawin B can be used for the research of leishmaniasis .
    Dihydroflavokawin B
  • HY-183362

    Parasite Adenosine Kinase Infection
    Antileishmanial agent-42 is an antileishmanial agent. Antileishmanial agent-42 has favorable interactions with key active site residues (e.g., Ser63, Asn66/295/299) of adenosine kinase. Antileishmanial agent-42 exerts activity against promastigote and amastigote forms of L. amazonensis, L. braziliensis, L. infantum, and L. donovani .
    Antileishmanial agent-42
  • HY-183290

    Parasite Reactive Oxygen Species (ROS) Infection
    Antileishmanial agent-41 (Compound 20k) is a selective Antileishmanial agent with a IC50 of 1.51 μg/mL against Leishmania donovani. Antileishmanial agent-41 increases ROS levels. Antileishmanial agent-41 can be used for the research of leishmaniasis .
    Antileishmanial agent-41

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: